**Table S1.** General characteristics of the animal models used in all studies included in the systematic review.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Country** | **Animal** | **Lineage** | **Sex** | **Age/Weight** | **Animals (n)\*** | **Control** |
| Kar et al., 1993 | IN | Hamster | Golden | ♂ | ?/? | ? | SSG, PET, ALO, TAA |
| Oliva et al., 1998 | IT | Domestic dogs | Various breeds | ? | 2-10 y/? | 32 | MEG, PAR |
| Carter et al 2003 | UK | Mice | Balb/c | ♀/♂ | ?/20-25g | ? | BSO, SSG |
| Haldar et al., 2009 | IN | Mice | Balb/c | ? | 4-6w/? | ? | PV6, SAG |
| Mutiso et al., 2011 | KE | Mice | Balb/c | ♀/♂ | 6-8 w/? | 30 | DIM, AMB, ART |
| Shakya et al., 2012a | IN | Mice | Balb/c | ♀/♂ | ?/18-20g | ? | MTF, Pam3Cys |
| Shakya et al., 2012b | IN | Mice | Balb/c | ♀/♂ | ?/18-20g | ? | MTF, TUF |
| Bhattacharjee et al., 2014 | IN | Mice | Balb/c | ? | 4-6w/? | 20 | SAG, GA |
| Corral et al., 2014 | ES | Hamster | ? | ♀ | ?/80-90g | 35 | AMB, ALL |
| Mwololo et al., 2015 | KE | Mice | Balb/c | ♀/♂ | 6-8 w/? | 40 | AMB, CHQ, DIM |
| Kahdem et al., 2016 | CA | Mice | Balb/c | ♀ | 6-8w/20g | ? | AMB, CAL-101 |
| Hendrickx et al., 2017 | BE | Hamster | Golden | ♀ | ?/80-100g | 45 | MTF, PAR |
| Joice et al., 2017 | US | Mice | Balb/c | ♀ | 6-8w/? | ? | POS, KET, MTF, DB766 |
| Rebello et al., 2019 | BR | Mice | Balb/c | ♀ | 6-8w/? | ? | MTF, LPV |

**ES**:Spain; **IN**:India; **CA**: Canada; **US**: United States of America; **IT**:Italy **KE**:Kenya; **BE**: Belgium; **BR**:Brazil; **y**: years; **w**: week; ♀: female; **♂**: male; **?**: data not reported; **POS**: Posaconazole; **SSG**: Sodium Stibogluconate; **SAG:** sodium antimony gluconate, **MEG**: Meglumine Antimoniate; **PAR**: Paromomycin; **MTF**: Miltefosine; **AMB**: Amphotericin B; **MET**: Metronidazole; **KET**: Ketoconazole**, TUF:** Tufinsin, **GA:** Glycyrrhizic acid, **ALL:** Allicin, **DIM:** Diminazene, **CAL-101:** p110δ-specific pharmacological inhibitors, **PAR:** Paromomycin, **LPV:** Lopinavir, **DB766:** 2,5-bis[2-(2-i-propoxy)-4-(2-pyridylimino) aminophenyl]furan hydrochloride, **Pam3Cys:** N-palmitoyl-S-(2, 3-bis (palmitoyloxy)-(2RS)-propyl)-Cys-Ser-Lys4.Hydrochloride), **ART:** Artesunate **CHQ:** Chloroquine, **PET:** Pentamidine, **ALO:** Allopurinol, **TAA:** *trans*-Aconiticc acid, **PV6:** Diperoxovanadate. \*Total number of animals investigated in each study.